Federated Hermes, Inc. Argenx Se Transaction History

Federated Hermes, Inc.

$43 Billion
Q4 2024

A detailed history of Federated Hermes, Inc. transactions in Argenx Se stock. As of the latest transaction made, Federated Hermes, Inc. holds 170,247 shares of ARGX stock, worth $110 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares

170,247

Previous 211,144 19.37%

Holding current value

$110 Million

Previous $115 Million 8.57%

% of portfolio

0.24%

Previous 0.26%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$520.52 - $638.33 $21.3 Million - $26.1 Million	-40,897 Reduced 19.37%	170,247 $105 Million
Q3 2024 Nov 13, 2024	SELL	$434.22 - $551.9 $18.8 Million - $23.9 Million	-43,246 Reduced 17.0%	211,144 $115 Million
Q2 2024 Aug 08, 2024	SELL	$356.01 - $451.55 $5 Million - $6.34 Million	-14,044 Reduced 5.23%	254,390 $109 Million
Q1 2024 May 14, 2024	SELL	$356.95 - $413.29 $31.4 Million - $36.4 Million	-88,073 Reduced 24.7%	268,434 $106 Million
Q4 2023 Jan 31, 2024	BUY	$338.91 - $506.01 $8.27 Million - $12.4 Million	24,416 Added 7.35%	356,507 $136 Million
Q3 2023 Nov 13, 2023	SELL	$369.35 - $548.43 $787,454 - $1.17 Million	-2,132 Reduced 0.64%	332,091 $163 Million
Q2 2023 Aug 14, 2023	SELL	$360.14 - $422.58 $4.32 Million - $5.07 Million	-11,991 Reduced 3.46%	334,223 $130 Million
Q1 2023 May 08, 2023	SELL	$334.23 - $403.65 $11 Million - $13.2 Million	-32,797 Reduced 8.65%	346,214 $129 Million
Q4 2022 Feb 13, 2023	SELL	$342.17 - $402.31 $22.1 Million - $26 Million	-64,626 Reduced 14.57%	379,011 $144 Million
Q3 2022 Nov 14, 2022	BUY	$343.2 - $395.75 $67,267 - $77,567	196 Added 0.04%	443,637 $157 Million
Q2 2022 Aug 15, 2022	SELL	$269.58 - $378.88 $4.09 Million - $5.75 Million	-15,181 Reduced 3.31%	443,441 $168 Million
Q1 2022 May 13, 2022	SELL	$254.45 - $351.06 $10.4 Million - $14.3 Million	-40,744 Reduced 8.16%	458,622 $145 Million
Q4 2021 Feb 14, 2022	BUY	$272.01 - $353.03 $17.8 Million - $23.1 Million	65,492 Added 15.09%	499,366 $175 Million
Q3 2021 Nov 15, 2021	SELL	$295.0 - $350.58 $346,625 - $411,931	-1,175 Reduced 0.27%	433,874 $131 Million
Q2 2021 Aug 16, 2021	SELL	$257.11 - $319.92 $7.78 Million - $9.68 Million	-30,266 Reduced 6.5%	435,049 $131 Million
Q1 2021 May 13, 2021	SELL	$268.3 - $380.31 $1.37 Million - $1.94 Million	-5,103 Reduced 1.08%	465,315 $128 Million
Q4 2020 Feb 12, 2021	SELL	$248.13 - $308.36 $227,783 - $283,074	-918 Reduced 0.19%	470,418 $138 Million
Q3 2020 Nov 12, 2020	BUY	$215.51 - $272.51 $1.36 Million - $1.72 Million	6,311 Added 1.36%	471,336 $124 Million
Q2 2020 Aug 13, 2020	BUY	$127.44 - $232.72 $12.8 Million - $23.4 Million	100,414 Added 27.54%	465,025 $105 Million
Q1 2020 May 13, 2020	SELL	$108.83 - $165.23 $891,317 - $1.35 Million	-8,190 Reduced 2.2%	364,611 $48 Million
Q3 2019 Nov 14, 2019	SELL	$113.31 - $150.51 $125,887 - $167,216	-1,111 Reduced 0.3%	372,801 $42.5 Million
Q2 2019 Aug 14, 2019	SELL	$115.0 - $141.58 $458,850 - $564,904	-3,990 Reduced 1.06%	373,912 $52.9 Million
Q1 2019 May 10, 2019	SELL	$98.85 - $134.59 $55.6 Million - $75.7 Million	-562,168 Reduced 59.8%	377,902 $47.2 Million
Q4 2018 Feb 13, 2019	SELL	$63.81 - $109.82 $1.35 Million - $2.33 Million	-21,206 Reduced 2.21%	940,070 $90.3 Million
Q3 2018 Nov 13, 2018	BUY	$75.5 - $96.63 $10.5 Million - $13.4 Million	138,531 Added 16.84%	961,276 $72.9 Million
Q2 2018 Aug 10, 2018	BUY	$74.84 - $100.16 $1.7 Million - $2.28 Million	22,745 Added 2.84%	822,745 $68.2 Million
Q4 2017 Feb 14, 2018	BUY	$22.57 - $63.56 $7.9 Million - $22.2 Million	350,000 Added 77.78%	800,000 $0
Q3 2017 Nov 13, 2017	BUY	$19.81 - $22.61 $8.91 Million - $10.2 Million	450,000	450,000 $10.1 Million

Others Institutions Holding ARGX

# of Institutions

432

Shares Held

29.2M

Call Options Held

390K

Put Options Held

272K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $35.7B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account

Federated Hermes, Inc. Argenx Se Transaction History